ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days. Show more

Location: 84 State St, Massachusetts, 02109-2202, US | Website: www.immunogen.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$31.23

Open

$31.23

Volume

40

Day Range

$31.23 - $31.23

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.32%

Institutional Own.

86.52%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Phase 2

Data readout

Pivekimab Sunirine (IMGN632) (Anti-CD123 ADC) Details
Blastic plasmacytoid dendritic cell neoplasm

Phase 2

Data readout

Phase 2

Data readout

IMGC936 Details
Solid tumor/s, Cancer, Triple-negative breast cancer

Phase 1

Data readout

IMGN151 (anti-ADAM9 ADC) Details
Cancer, Solid tumor/s, Endometrial cancer

Phase 1

Data readout